Compare CUBI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | IMNM |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United States | United States |
| Employees | 869 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | N/A | 2020 |
| Metric | CUBI | IMNM |
|---|---|---|
| Price | $76.47 | $18.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $85.00 | $32.80 |
| AVG Volume (30 Days) | 275.2K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $24.95 | N/A |
| Revenue Next Year | $9.50 | $1,127.34 |
| P/E Ratio | $11.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.25 | $7.96 |
| 52 Week High | $82.56 | $27.65 |
| Indicator | CUBI | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 33.00 |
| Support Level | $71.61 | $16.81 |
| Resistance Level | $79.11 | $19.16 |
| Average True Range (ATR) | 1.82 | 0.92 |
| MACD | 0.32 | -0.21 |
| Stochastic Oscillator | 62.70 | 1.24 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.